The National Cancer Institute’s website explains targeted therapies as a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. It is the foundation of precision medicine. As researchers learn more about the DNA changes and proteins that drive cancer, they are better able to design treatments that target these proteins. The purpose of this webinar is to provide an overview of current research of targeted therapies as demonstrated by the efforts of Endeavor BioMedicines and EndBrainCancer.
A brief overview of clinical trials will be discussed with topics including, the benefits of choosing a trial as a therapy option, current programs offered to help with barriers associated with clinical trials and how to find the right trial. In addition, a Patient Advocacy Group Representative will present information about resources and their efforts for patients who are trying to navigate their way into new forms of treatment options and how the navigators work from a patient advocacy standpoint.
At the end of the webinar, the featured speakers will open the floor for questions and answers as well as an interactive discussion on clinical trial perception and barriers. Oncology nurses and nurse/patient navigators might especially find this webinar useful, with tools and resources to best help their current and future patients.
Register today to learn more about advances in precision medicine, NGS testing and breaking barriers with clinical trials.
Anita DiFrancesco, VP Clinical Operations, Endeavor BioMedicines
Ms. Anita DiFrancesco has over 25 years of industry experience; primarily with small to mid-size biotech companies. She has designed and managed numerous clinical trials from Phase 1 to Phase 3 in therapeutic areas including oncology, pulmonology, musculoskeletal and pain. Ms. DiFrancesco has built teams and clinical departments from inception to fully functional independent internal teams. Prior to joining Endeavor, Anita was the Vice President of Clinical Operations for Samumed, LLC, where she was responsible for the management and leadership of the Clinical Operations department. Prior to that she worked at Huya Bioscience, Cypress Bioscience and Chiron Corporation. She received her BS from Georgetown University.
Dellann Elliott Mydland, Patient Advocate and Business Leader, EndBrainCancer
Due to her personal experience with brain cancer, Dellann has worked tirelessly on behalf of cancer & brain tumor patients, caregivers and their families for over 20 years since co-founding the Chris Elliott Fund, now doing business as the EndBrainCancer Initiative (EBCI). Dellann is, at once, a patient advocate, entrepreneur, educator, mentor, visionary, and creator of a unique “Customer Support Type of Advocacy/Disease Education, Awareness & Outreach Program/Service” & the “Direct Connect” Referral Program/Service model, that other Advocacy organizations have and are now replicating which has an emphasis on 1:1 personalized delivery of disease education, and “direct connect” via text/email and phone connections to specialists,2nd options and clinical trial access. This model benefits patients and their families while also benefiting the research community alike, in that it directly connects newly diagnosed, recurrent and metastatic brain cancer patients across the country with top brain tumor neurosurgeons, neurooncologists, radiation oncologists, principal investigators/researchers, genomic & molecular profiling (Next Generation Sequencing), advanced treatments, clinical trials, targeted treatments, immunology/vaccines, and personalized medicine. This approach ultimately creates greater Quality of Life for the patient, increases research data, increases treatment options and improves Standard of Care (SOC) for all, therefore, improving survivorship.
Dellann “views IMMEDIATE ACCESS to all of the above as essential for providing HOPE to the brain tumor patient and rare disease communities, improving patient outcomes & quality of life, advancing research, improving clinical trial development access as well as improving Standard of Care and Clinical Practice for all cancer patients.”
Dellann is a skilled public advocate, testifying at hearings for new treatment options/FDA approval and proper reimbursement coding for treatments/devices, etc. in Washington, D.C. and around the country, educating legislatures, doctors and patients personally and through multimedia disease educational campaigns while driving collaboration within the research community at all junctures. She is a regular contributor to leading brain tumor and oncology patient awareness and education publications, including peer reviewed publications and actively participates as a Patient Advocate providing the
“Patient Voice” for cancer and brain cancer clinical trials to multiple Clinical Trail Organizations (CRO’s), Drug/Device/NGS, City of Hope, California Institute for Regenerative Medicine, John Hopkins, Yale, etc., clinical trial sponsors and Institutions while also sitting on multiple Patient Advocacy Industry Boards. Dellann actively advocates on behalf of patients with brain cancer responding to Advocacy opportunities for improved access to CMS/Medicare and health insurance coverage, FDA new treatment option approvals, improvements to FDA’s clinical trial approval process to include a more diverse group of participants as well as coverage related to advanced diagnostics, such as Next Generation Genomic Sequencing. Dellann most recently served as the brain cancer patient advocate for NRG Oncology on both the neuro/clinical trial and neuro-surgery committees. In addition, Dellann has consulted as a patient advocate on multiple pediatric and adult brain cancer patient clinical trials for Genentech, Arbor Pharmaceuticals, Novocure, etc. as well as has been named on several research project applications to NCI/NIH as the brain tumor Patient Advocate of choice and has created/edited multiple patient disease educational brochures/websites/videos, etc. on behalf of the pharmaceuticals industry. Dellann is a past recipient of the National Brain Cancer Advocate HOPE Award and was chosen by Harvard and Dana-Farber Cancer Institute as their choice for patient advocate for a GBM “Stand-Up to Cancer” funded research project. Dellann’s leads her organization’s “NCI-CONNECT” clinical trial education/outreach program & partnership efforts as well as EBCI’s patient/caregiver referral “Direct Connect” program and partnership efforts with the Brain Tumor Network (BTN). In addition, she serves on multiple pharma/industry Patient Advocacy Boards and is a member of the Society of Neurooncology (SNO), merican Association Clinical Research (AACR), among others. Her consultation fee is $275/hour.
A Bachelor’s in Education, multiple business classes such as Accounting, Business Law, Public Speaking, Economics, etc., non-profit management courses & experience, marketing and sales background as well as her many years in regulatory coordination and management and a crash course on GBM treatments/science/clinical trials/next generation sequencing, etc. make Dellann uniquely qualified as EBCI’s CEO, President & Board Chair to lead EBCI’s mission, Board and Team, teach advocacy, program and the “patient voice” as well as develop and manage disease education programing, including all aspects of awareness & outreach as well excelling at hosting and leading interviews and online disease education programming, meetings and events for the last 20 years.
To learn more about Dellann’s work, the EndBrainCancer Initiative’s focus, day-to-day work and IMPACT as well as how to best partner on mutual goals, visit www.EndBrainCancer.org to learn more/fill out a Corporate Partner Form” or contact her directly at [email protected], 425-785-8489.
Dellann also serves as a paid advisor on AdvisoryCloud.
Additional information related to Dellann’s Advocacy, Leadership, Inspiration and IMPACT efforts and experience can be found on/at:
Corporate Magazine Feature: https://thecorporatemagazine.com/making-adifference-in-healthcare-dellann-elliott-mydland/
Who Should Attend?
- Nurse Navigators
- Patient Advocate Trial Navigators
- Oncology Nurses
- Oncology Patients
- Residential Oncologists
- Patient Advocates
What You Will Learn
Attendees will gain insights into:
- The definition of targeted therapies and how they differ from traditional therapies
- Current research in targeted therapies as demonstrated by sponsor compounds
- Clinical trials in targeted therapies
- Patient advocacy resources
- Clinical trial/patient resources
- Advancements in NGS testing
Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis. We combine advancements in technology with an evolving understanding of terminal diseases to develop best-in-class medicines with the potential to reverse the most severe health conditions. We are a highly qualified, innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.
The Chris Elliott Fund is furiously committed to finding a cure for brain cancer and to bringing HOPE to the lives of patients and their families.
Everything we do is directed towards our ultimate mission, which is to End Brain Cancer within our lifetimes. We are unique in the one-on-one personalized support we offer to brain tumor patients and their families.
- Provide patients with IMMEDIATE ACCESS to advanced treatment options, specialists & comprehensive support programs
- Provide support & guidance concerning the DAY-TO-DAY needs of patients and their caregivers
- Educate the general public on matters related to brain tumors and brain cancer
- Advocate on issues of national public health policy impacting the lives and welfare of brain tumor patients/brain cancer patients
Our ultimate goal is to put ourselves out of business when a cure is found for brain cancer and our services are no longer needed.